---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-037084"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T13:58:53.957039+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Moleculin partners with CIC biomaGUNE for preclinical Annamycin glioblastoma study

## Summary
- Agreement supplies Annamycin for investigator-initiated preclinical research at CIC biomaGUNE, Spain.
- Studies compare intra-arterial L-Annamycin and Free-Annamycin vs Doxil and free doxorubicin in mouse GBM models.
- Principal investigator Jesús Ruiz-Cabello to lead the evaluation of tumor progression.
- Annamycin holds FDA Fast Track and Orphan Drug Designation for AML and STS lung metastases.
- GBM is the most common malignant brain tumor with median survival of 15 months.

## SEC filing metadata
- accession: 0001437749-25-037084
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925037084/0001437749-25-037084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925037084/mbrx20251205_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-037084
- JSON: https://secwatch.observer/filing/0001437749-25-037084.json
- Plain text: https://secwatch.observer/filing/0001437749-25-037084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.